EUVIMEDEUVIMED entdecken
Open Access

Real-world evidence on the use of hospital resources for subcutaneous and intravenous trastuzumab administration in breast cancer patients at a referral public hospital in Mexico

Tatiana Fiordelisio iD, Francisco Valdés-Souto iD, Diana Del-Rio Valdes iD, Diego Zamarrón Hernández iD, Karla Ramírez Pulido iD, Cristopher Alejandro Escamilla Soto iD, Yair Uriel Correa Trejo iD, Claudia Itzel Gutiérrez Sánchez, Isabel Espino Gutiérrez, Claudia Haydeé Arce Salinas iD

Journal of Comparative Effectiveness Research · 2026-05 · 15 (5)

DOI: 10.57264/cer-2025-0199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-05. Verfasst von Tatiana Fiordelisio und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia, Facultad de Ciencias, Universidad Nacional Autónoma de México (UNAM), Alc…. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The availability of subcutaneous (SC) trastuzumab has introduced a practical alternative to traditional intravenous (IV) delivery for HER2-positive breast cancer. Beyond clinical equivalence, the shift toward SC administration offers the possibility of reorganizing workflow, reducing the pressure on infusion units and improving the treatment experience for both patients and healthcare professionals. This study provides real-world evidence from a large public oncology hospital in Mexico City, examining how SC and IV trastuzumab compare in everyday practice with respect to treatment times, resources use and the perceptions of patients and staff. Materials & methods: A prospective time and motion study was conducted to compare the efficiency and operational impact of SC and IV routes of trastuzumab administered as monotherapy in women with HER2-positive breast cancer at a public hospital in Mexico City. Sixty administrations (30 SC and 30 IV) were analyzed, recorded in real time using a digital system specifically developed for this study. The system documented waiting times, preparation, administration and time spent in the treatment room. Resource utilization was estimated based on the average number of supplies required for each route. In addition, patients and healthcare personnel completed structured questionnaires on comfort, satisfaction and overall experience.

Results

Treatment using the SC route was noticeably shorter. Compared with the IV route, median chair time and overall procedure duration dropped by close to 94%, and treatment room occupancy decreased by approximately 83%. This route also required fewer materials and avoided the drug loss due to weight-based IV dosing. Patients described the SC injection as more comfortable and less fatiguing, while healthcare professionals noted less physical effort, lower stress levels and a more manageable workflow.

Conclusion

In a routine public oncology setting with limited resources, the use of SC trastuzumab was associated with clear advantages in terms of efficiency and the treatment experience while also mitigating the workload of infusion areas. These results provide practical, context-specific evidence that could help healthcare systems to improve the organization of oncology services and make better use of scarce hospital resources.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabBreast NeoplasmsAntineoplastic Agents, ImmunologicalHumansFemaleMexicoHospitals, PublicProspective StudiesInjections, SubcutaneousMiddle AgedAdultTime and Motion StudiesInfusions, IntravenousPatient Satisfaction

Stichwörter der Autor:innen

breast cancerreal-world evidencesubcutaneous vs intravenoustime-and-motion studytrastuzumab

Substanzen

TrastuzumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Laboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia, Facultad de Ciencias, Universidad Nacional Autónoma de México (UNAM), Alcaldía Coyoacán, Ciudad de México, México.
  • Facultad de Ciencias, Universidad Nacional Autónoma de México (UNAM), Alcaldía Coyoacán, Ciudad de México, México.
  • Departamento de Oncología Médica, Instituto Nacional de Cancerología (INCan), Alcaldía Tlalpan, Ciudad de México, México.

ORCID-Profile: Tatiana Fiordelisio, Francisco Valdés-Souto, Diana Del-Rio Valdes, Diego Zamarrón Hernández, Karla Ramírez Pulido, Cristopher Alejandro Escamilla Soto, Yair Uriel Correa Trejo, Claudia Haydeé Arce Salinas

Zitieren

APA

Fiordelisio, T., Valdés-Souto, F., Valdes, D. D., Hernández, D. Z., Pulido, K. R., Escamilla Soto, C. A., Correa Trejo, Y. U., Gutiérrez Sánchez, C. I., Gutiérrez, I. E., & Arce Salinas, C. H. (2026). Real-world evidence on the use of hospital resources for subcutaneous and intravenous trastuzumab administration in breast cancer patients at a referral public hospital in Mexico. Journal of Comparative Effectiveness Research, 15(5). https://doi.org/10.57264/cer-2025-0199

Vancouver

Fiordelisio T, Valdés-Souto F, Valdes DD, Hernández DZ, Pulido KR, Escamilla Soto CA, et al. Real-world evidence on the use of hospital resources for subcutaneous and intravenous trastuzumab administration in breast cancer patients at a referral public hospital in Mexico. Journal of Comparative Effectiveness Research. 2026;15(5). doi:10.57264/cer-2025-0199

BibTeX
@article{Fiordelisio2026,
  author = {Fiordelisio, Tatiana and Valdés-Souto, Francisco and Valdes, Diana Del-Rio and Hernández, Diego Zamarrón and Pulido, Karla Ramírez and Escamilla Soto, Cristopher Alejandro and Correa Trejo, Yair Uriel and Gutiérrez Sánchez, Claudia Itzel and Gutiérrez, Isabel Espino and Arce Salinas, Claudia Haydeé},
  title = {Real-world evidence on the use of hospital resources for subcutaneous and intravenous trastuzumab administration in breast cancer patients at a referral public hospital in Mexico},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.57264/cer-2025-0199}
}
Kostenlos starten →